Kathy High, a scientist and executive who led the development of the first gene therapy approved in the U.S., has left Bayer subsidiary AskBio two years after joining.
An AskBio spokesperson confirmed her departure, adding in an email that High “decided to leave AskBio to begin a sabbatical at Rockefeller University and spend more time with her family, before focusing on ventures in new spaces.”
High, in a brief interview, didn’t comment directly on her reasons for leaving but noted she is now a visiting fellow at Rockefeller University and praised the biotech and its technology.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect